Hangzhou Huasai Biomedicine Co., Ltd. clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)

   Primary completion pushed from Aug 30, 2026 to Aug 30, 2027

   Also in this update: Recruitment opened; Start date changed from estimate of Aug 30, 2025 to Aug 30, 2026

   Hangzhou Huasai Biomedicine Co., Ltd.·Phase 1· NCT07105176· Registry history of NCT07105176 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Notable

   HS-IT101 Injection · Advanced Non-Small Cell Lung…HS-IT101 Injection · Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)

   Primary and study completion pushed from Oct 2027 to Oct 2028

   Also in this update: Primary endpoint(s) modified; Sponsor changed: Qingdao Sino-Cell Biomedicine Co., Ltd. to Hangzhou Huasai Biomedicine Co., Ltd.

   Hangzhou Huasai Biomedicine Co., Ltd.·Phase 1· NCT07830342· Registry history of NCT07830342 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

3. Notable

   HS-IT101 Injection · Advanced Renal Cancer(FASTIL-Renal01)

   Primary completion pushed from Oct 2026 to Aug 2028

   Also in this update: Primary endpoint(s) modified; Sponsor changed: Qingdao Sino-Cell Biomedicine Co., Ltd. to Hangzhou Huasai Biomedicine Co., Ltd.

   Hangzhou Huasai Biomedicine Co., Ltd.·Phase 1· NCT07770802· Registry history of NCT07770802 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.